SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is seeing strong bullish sentiment as investors anticipate upcoming earnings, fueled by optimism over its AI infrastructure buildout and a raised price target from Morgan Stanley. While some traders are wary of potential volatility and high capital expenditure, many remain focused on the stock's long-term growth potential in the cloud sector.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

The conversation is dominated by anticipation for the upcoming Investor Day, with traders debating the company's growth strategy, recent acquisitions, and technological milestones. While some investors express bullish sentiment regarding the firm's leadership in the quantum sector and potential revenue expansion, others voice skepticism, questioning the company's financial fundamentals and technical progress compared to industry peers.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

Rigetti Computing and other quantum sector peers are rallying following the finalization of a 100 million dollar funding agreement with the U.S. Department of Commerce under the CHIPS and Science Act. While the broader quantum industry is trending, investors remain divided between optimistic sentiment regarding long-term technical potential and concerns over current valuation and bearish retail sentiment.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum is trending following the finalization of a $100 million funding agreement with the U.S. Department of Commerce under the CHIPS and Science Act. While some traders view this government backing as a significant long-term validator for the company's quantum technology, others remain focused on the firm's financial volatility and ongoing management changes.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is experiencing significant price volatility and trending interest as the community debates the impact of competitor Novartis's Phase 3 DM1 trial failure on the broader muscular dystrophy space. While some traders fear a read-through risk that suggests a ceiling for DMPK knockdown therapies, others view the development as a competitive advantage for Sarepta and are looking toward upcoming clinical data readouts as a potential catalyst for a re-rating.

Intellia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellia Therapeutics is trending as traders speculate on a potential short squeeze and upcoming regulatory catalysts, including the completion of its rolling Biologics License Application (BLA) and expected commercialization in 2027. Despite persistent bearish sentiment regarding potential dilution and competition, bullish investors point to strong institutional accumulation and clinical data as key indicators of long-term value.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood is trending as shares rally following strong growth in its new prediction markets and Robinhood Chain fee revenue, along with the company securing its first IPO underwriting mandate. While investors express enthusiasm over these growth catalysts and recent analyst price target increases, community discourse remains polarized by lingering skepticism from some traders regarding the brokerage's past regulatory issues and current business practices.

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. Its product portfolio is heavily focused on innovative prescription medicines, especially oncology, immunology, neuroscience, and cardiovascular diseases, supplemented by established older brands and a wide range of specialized therapies. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Novartis AG - ADR

Novartis AG

The community is focused on the recent failure of a Phase 3 study for Novartis' del-desiran (a muscle-focused drug), which has negatively impacted the broader neuromuscular disease space. Traders are debating whether these clinical setbacks will pressure the company to accelerate its acquisition strategy as it approaches upcoming patent expirations.

Quantum Computing, Inc. engages in developing novel algorithms and solutions utilizing quantum and quantum-inspired computing to solve difficult problems in various industries. It leverages its expertise in finance, computing, security, mathematics, and physics to develop commercial applications for the financial, security, and government sectors. The company was founded on July 25, 2001 and is headquartered in Hoboken, NJ.

Quantum Computing Inc

Quantum Computing Inc. is seeing intense discussion regarding its significant short interest and potential for a squeeze, with many traders pointing to the company's substantial cash position and institutional accumulation as a bullish floor. While some community members highlight the stock's undervaluation relative to peers and long-term potential in photonics and hardware, others express frustration with the recent price stagnation and are waiting for major contract announcements to serve as a catalyst.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is trending as the community anticipates imminent Phase 1 maintenance study data for its weight loss drug, VK2735. Traders are expressing strong conviction in the drug's potential, with many speculating on the possibility of a buyout or partnership, though some remain cautious about price volatility and management's past execution.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 
